Endophthalmitis
What new strategies are in the pipeline to treat corneal infections?
There are two lines of research we are pursuing in our lab currently.
Intracameral antibiotic prophylaxis: Where do we stand?
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
UK-based real-world study shows effective, long-lasting outcomes of faricimab in DME
BARCELONA, Spain — A large amount of real-world data collected from clinics across the U.K. highlighted the effectiveness, safety and durability of faricimab for diabetic macular edema in treatment-naive and previously treated eyes.
Phase 2b trial of CLS-AX for wet AMD achieves primary, secondary outcomes
A phase 2b clinical trial of CLS-AX, a tyrosine kinase inhibitor under evaluation for the treatment of wet age-related macular degeneration, achieved its primary and secondary outcomes, according to a Clearside Biomedical press release.
Endophthalmitis rates after intraocular procedures declined over past 2 decades
A study covering a large U.S. database over 22 years found a steady decrease in the rate of endophthalmitis after intraocular procedures.
Glove use does not impact post-injection endophthalmitis but affects carbon footprint
Wearing gloves for intravitreal injections does not decrease the risk for endophthalmitis but does take up time and has a significant carbon footprint, according to a study.
Comparable efficacy, safety found for wet AMD anti-VEGF biosimilars vs. reference drugs
A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.
No scleral fixation technique comes without challenges
FORT LAUDERDALE, Fla. — Secondary IOL implantation techniques have equivalent visual acuity results and safety profiles, along with inherent risks and postoperative complications, according to a speaker at the Retina World Congress.
Advancements continue in development of retinal disease treatments
An intravitreal injection is now the most common surgical procedure performed in the United States by an ophthalmologist.
Phase 2 nonproliferative diabetic retinopathy trial misses primary endpoint
SEATTLE — The phase 2 PAVIA trial investigating Duravyu, previously known as EYP-1901, for the treatment of nonproliferative diabetic retinopathy did not meet its primary endpoint, according to a press release from EyePoint Pharmaceuticals.